Jason Paragas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jason Paragas has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Aura R. Garrison
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, USA
1 shared publication Chris Hartmann
Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street, Fort Detrick, MD 21702-5011, USA
1 shared publicationDavid A Kulesh
Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America
1 shared publicationDavid A Norwood
Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America
1 shared publicationElizabeth A Fritz
Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America
1 shared publicationElizabeth Vitalis
Lawrence Livermore National Laboratory, Livermore, California, United States of America
1 shared publication
Latest Publications
- Open Access
- 18 April 2006
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 3 (5) , e149
Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome
The emergence of severe acute respiratory syndrome (SARS) in 2002 and 2003 affected global health and caused major economic disruption. Adequate animal models are required to study the underlying pathogenesis of SARS-associated coronavirus (SARS-CoV) infection and to develop effective vaccines and therapeutics. We report the first findings of measurable clinical disease in nonhuman primates (NHPs) infected with SARS-CoV. In order to characterize clinically relevant parameters of SARS-CoV infection in NHPs, we infected cynomolgus macaques with SARS-CoV in three groups: Group I was infected in the nares and bronchus, group II in the nares and conjunctiva, and group III intravenously. Nonhuman primates in groups I and II developed mild to moderate symptomatic illness. All NHPs demonstrated evidence of viral replication and developed neutralizing antibodies. Chest radiographs from several animals in groups I and II revealed unifocal or multifocal pneumonia that peaked between days 8 and 10 postinfection. Clinical laboratory tests were not significantly changed. Overall, inoculation by a mucosal route produced more prominent disease than did intravenous inoculation. Half of the group I animals were infected with a recombinant infectious clone SARS-CoV derived from the SARS-CoV Urbani strain. This infectious clone produced disease indistinguishable from wild-type Urbani strain. SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children.
- 18 April 2006
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 3 (5) , e149
Open AccessCynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome
The emergence of severe acute respiratory syndrome (SARS) in 2002 and 2003 affected global health and caused major economic disruption. Adequate animal models are required to study the underlying pathogenesis of SARS-associated coronavirus (SARS-CoV) infection and to develop effective vaccines and therapeutics. We report the first findings of measurable clinical disease in nonhuman primates (NHPs) infected with SARS-CoV. In order to characterize clinically relevant parameters of SARS-CoV infection in NHPs, we infected cynomolgus macaques with SARS-CoV in three groups: Group I was infected in the nares and bronchus, group II in the nares and conjunctiva, and group III intravenously. Nonhuman primates in groups I and II developed mild to moderate symptomatic illness. All NHPs demonstrated evidence of viral replication and developed neutralizing antibodies. Chest radiographs from several animals in groups I and II revealed unifocal or multifocal pneumonia that peaked between days 8 and 10 postinfection. Clinical laboratory tests were not significantly changed. Overall, inoculation by a mucosal route produced more prominent disease than did intravenous inoculation. Half of the group I animals were infected with a recombinant infectious clone SARS-CoV derived from the SARS-CoV Urbani strain. This infectious clone produced disease indistinguishable from wild-type Urbani strain. SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS; however, our results suggest similarities to the milder syndrome of SARS-CoV infection characteristically seen in young children.
- Open Access
- 15 February 2005
- Published by Elsevier in Antiviral Research
- Vol. 66 (2-3) , 99-102
Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
- 15 February 2005
- Published by Elsevier in Antiviral Research
- Vol. 66 (2-3) , 99-102
Open AccessInterferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models